Medreich Australia Pty Ltd Pharmaceutical Import Profile — Australia (DGFT 2022–2026)

Name: Medreich Australia Pty Ltd Pharmaceutical Import Records from India — 7 Products, $5.4M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Medreich Australia Pty Ltd — Pharmaceutical Importer Profile (2026) | 7 Products, $5.4M Trade | TransData Nexus

Medreich Australia Pty Ltd

Pharmaceutical Importer · Australia · Antihistamines & Allergy Focus · $5.4M Total Trade · DGFT Verified

Medreich Australia Pty Ltd is a pharmaceutical importer based in Australia with a total trade value of $5.4M across 7 products in 4 therapeutic categories. Based on 465 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Medreich Australia Pty Ltd sources from 1 verified Indian supplier, with Medreich Limited accounting for 100.0% of imports.

Medreich Australia Pty Ltd — Import Portfolio & Supplier Network

Medreich Australia Pty Ltd import network — 7 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Medreich Australia Pty Ltd?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Medreich Limited	$19.1M	1,303	100.0%

Medreich Australia Pty Ltd sources from 1 verified Indian supplier across 769 distinct formulations. The sourcing is highly concentrated — Medreich Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Medreich Australia Pty Ltd Import?

Formulation	Value	Ships
Amoxicillin and potassium clavulanate	$1.2M	32
Pharmacychoicecold&flu+cough	$289.7K	9
Domperidone tablets 10MG (apo	$284.2K	10
Loratadine 10MG tablets (demazin	$266.1K	12
Amoxicillin 500MG capsules (amiloxyn)	$235.2K	6
Ibuprofen tablets 200MG (wagner health	$223.4K	16
Wagner health ibuprofen 200MG	$204.4K	8
Cetirizine hydrochloride tablets 10MG	$199.3K	18
Wagner health ibuprofen 200MG	$194.7K	7
Amoxicillin 500MG capsules (amiloxyn)	$185.2K	4
Para500mg+phenylephine	$180.8K	5
Amoxicillin 500 MG capsules (amiloxyn)	$151.9K	4
Diclofenac sodium tablets	$140.6K	4
Fexofenadine hydrochloride 180MG tabs	$139.5K	5
Fexofenadine hydrochloride tablets 180MG	$133.2K	9

Import Portfolio — Top 7 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Loratadine	Antihistamines & Allergy	$1.7M	146	1.0%	8
2	Fexofenadine	Antihistamines & Allergy	$1.4M	75	1.2%	19
3	Loperamide	Gastrointestinal	$802.7K	78	1.1%	5
4	Codeine	Analgesics & Antipyretics	$482.3K	28	0.4%	13
5	Domperidone	Gastrointestinal	$388.5K	15	1.3%	9
6	Aspirin	Analgesics & Antipyretics	$387.9K	61	1.0%	18
7	Bromhexine	Respiratory & OTC	$215.3K	62	1.3%	9

Medreich Australia Pty Ltd imports 7 pharmaceutical products across 4 categories into Australia totaling $5.4M.

Medreich Australia Pty Ltd — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Medreich Australia Pty Ltd is an Australian proprietary company, incorporated on 26 May 2006, with its head office located in Homebush, New South Wales. As a subsidiary of Medreich Limited, a fully integrated pharmaceutical company based in Bengaluru, India, Medreich Australia specializes in the importation and wholesaling of generic medicines. The company has been operational since 2006, focusing on supplying over-the-counter (OTC) and prescription (Rx) products manufactured by its parent company, Medreich Limited, to pharmaceutical companies across Australia and New Zealand.

Medreich Australia plays a significant role in the Australian pharmaceutical distribution network by acting as a bridge between Indian pharmaceutical manufacturers and the Australian market. By importing a diverse range of generic medicines, the company contributes to enhancing the availability and affordability of essential medications in Australia. Its operations encompass regulatory compliance, quality assurance, logistics, sales, marketing, and new product development, supported by teams in both Australia and India.

2Distribution Network

Medreich Australia's distribution network is centered around its head office in Homebush, New South Wales. While specific details about additional warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic position in Sydney facilitates efficient distribution across Australia and New Zealand. The proximity to major ports and transportation hubs enables timely and reliable delivery of pharmaceutical products to various stakeholders in the region. Medreich Australia's logistics operations are supported by its parent company's extensive experience in handling controlled substances and managing complex supply chains.

3Industry Role

In Australia's pharmaceutical supply chain, Medreich Australia Pty Ltd functions primarily as a pharmaceutical importer and wholesaler. By sourcing generic medicines from its parent company, Medreich Limited, and other suppliers, the company ensures a steady supply of affordable medications to the Australian market. Its role is crucial in bridging the gap between international manufacturers and local pharmaceutical companies, thereby enhancing the accessibility of essential drugs. Medreich Australia's operations encompass regulatory compliance, quality assurance, logistics, sales, marketing, and new product development, supported by teams in both Australia and India.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Medreich Australia Pty Ltd

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Medreich Australia's sourcing strategy exhibits a high degree of concentration, with a significant reliance on a single supplier, Medreich Limited. This dependency is evident from the data indicating that Medreich Limited accounts for 100% of the company's imports from India, amounting to $19.1 million across 1,303 shipments. Such concentration can present risks, including potential supply chain disruptions due to geopolitical issues, regulatory changes, or operational challenges within the supplier's facilities. However, this focused sourcing approach may also offer benefits such as streamlined operations, consistent product quality, and favorable pricing agreements. The stability of the relationship between Medreich Australia and Medreich Limited is crucial for maintaining uninterrupted supply and meeting market demands.

2Supply Chain Resilience

The resilience of Medreich Australia's supply chain is closely tied to the operational stability of Medreich Limited. Given the exclusive sourcing arrangement, any disruptions within Medreich Limited's manufacturing or distribution processes could directly impact Medreich Australia's ability to supply products to the Australian market. To mitigate such risks, it is essential for Medreich Australia to maintain robust contingency plans, including identifying alternative suppliers and ensuring compliance with Australian regulatory standards. Additionally, diversifying the supplier base and incorporating a broader range of formulations could enhance supply chain resilience and reduce dependency on a single source.

Importing Pharmaceuticals into Australia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Australia

1Regulatory Authority & Framework

In Australia, the regulation of pharmaceutical imports is overseen by the Therapeutic Goods Administration (TGA), which ensures that all therapeutic goods, including medicines, meet the required standards for quality, safety, and efficacy. The primary legislation governing pharmaceutical imports is the Therapeutic Goods Administration Act 1989, which outlines the requirements for the registration, importation, and supply of therapeutic goods in Australia. For Indian generics to be marketed in Australia, they must be included in the Australian Register of Therapeutic Goods (ARTG), a process that involves comprehensive evaluation and approval by the TGA. (tga.gov.au)

2Import Licensing & GMP

Import licensing requirements in Australia stipulate that therapeutic goods must be entered in the ARTG before they can be legally imported. This process ensures that all imported medicines comply with Australian standards. Good Manufacturing Practice (GMP) certification is mandatory for manufacturers of imported medicines. The TGA recognizes GMP certificates from various international regulatory bodies, including the European Union (EU), World Health Organization (WHO), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Indian manufacturers seeking to export to Australia must ensure their facilities are GMP-compliant and that their products are registered in the ARTG. (tga.gov.au)

Medreich Australia Pty Ltd — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Medreich Australia Pty Ltd's product strategy focuses on importing generic medicines across various therapeutic categories, with a significant emphasis on antihistamines and allergy treatments, gastrointestinal medications, and analgesics and antipyretics. This focus aligns with the prevalent health concerns in the Australian population, where conditions such as allergies, gastrointestinal disorders, and pain management are common. By concentrating on these therapeutic areas, Medreich Australia aims to meet the market demand for affordable and effective treatments, thereby enhancing patient care and expanding its market presence.

2Sourcing Profile

Medreich Australia's sourcing strategy is centered on importing generic drugs from its parent company, Medreich Limited, which manufactures a wide range of pharmaceutical products. The company imports finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, rather than raw active pharmaceutical ingredients (APIs) or bulk drugs. This approach allows Medreich Australia to offer a diverse product portfolio to the Australian market, ensuring a steady supply of essential medicines. India's established pharmaceutical manufacturing capabilities and compliance with international GMP standards make it a reliable source for these products.

3Market Positioning

Seller's Guide — How to Become a Supplier to Medreich Australia Pty Ltd

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter Medreich Australia's supply chain, provided they can meet the stringent regulatory and quality standards required by the Australian market. Diversifying the supplier base could enhance supply chain resilience and reduce dependency on a single source. To establish a partnership, Indian exporters must ensure their products are registered in the ARTG, comply with Australian GMP standards, and meet labeling and packaging requirements. Building a strong relationship with Medreich Australia would involve demonstrating product quality, reliability, and a commitment to regulatory compliance.

2Requirements & Qualifications

Indian exporters seeking to supply Medreich Australia Pty Ltd and the Australian market must ensure their products are registered in the ARTG and comply with Australian GMP standards. Manufacturing facilities should hold valid GMP certificates recognized by the TGA, such as those from the EU, WHO, or PIC/S. Products must meet Australian labeling and packaging requirements,

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Medreich Australia Pty Ltd

What products does Medreich Australia Pty Ltd import from India?

Medreich Australia Pty Ltd imports 7 pharmaceutical products across 4 categories. Top imports: Loratadine ($1.7M), Fexofenadine ($1.4M), Loperamide ($802.7K), Codeine ($482.3K), Domperidone ($388.5K).

Who supplies pharmaceuticals to Medreich Australia Pty Ltd from India?

Medreich Australia Pty Ltd sources from 1 verified Indian suppliers. The primary supplier is Medreich Limited (100.0% of imports, $19.1M).

What is Medreich Australia Pty Ltd's total pharmaceutical import value?

Medreich Australia Pty Ltd's total pharmaceutical import value from India is $5.4M, based on 465 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Medreich Australia Pty Ltd focus on?

Medreich Australia Pty Ltd imports across 4 categories. The largest: Antihistamines & Allergy (57.5%), Gastrointestinal (22.2%), Analgesics & Antipyretics (16.2%).

Get Full Medreich Australia Pty Ltd Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.